Literature DB >> 22899350

Breast cancer proteome takes more than two to tango on TRAIL: beat them at their own game.

Ammad Ahmad Farooqi1, Sundas Fayyaz, Muhammad Tahir, Muhammed Javed Iqbal, Shahzad Bhatti.   

Abstract

Breast carcinogenesis is a multidimensional disease that has resisted drug-related solutions to date because of heterogeneity, disorganized spatiotemporal behavior of signal transduction cascades, cell cycle checkpoints, cell transition, plasticity, and impaired pro-apoptotic response. These synchronized oncogenic events, including protein-protein interaction, transcriptional-regulatory, and signaling networks, trigger genomic and transcriptional disturbances in TRAIL-mediated signaling network neighborhoods. Therefore, tumor cells often acquire the ability to escape death by suppressing cell death pathways that normally function to eliminate damaged and harmful cells. This review describes the TRAIL-mediated cell death signaling pathways, the interactions between these pathways, and the ways in which these pathways are deregulated in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899350     DOI: 10.1007/s00232-012-9490-y

Source DB:  PubMed          Journal:  J Membr Biol        ISSN: 0022-2631            Impact factor:   1.843


  112 in total

1.  Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles.

Authors:  Ashlynn L Z Lee; Yong Wang; Shazib Pervaiz; Weimin Fan; Yi Yan Yang
Journal:  Macromol Biosci       Date:  2010-12-08       Impact factor: 4.979

2.  TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells.

Authors:  Yuhui Jiang; Kai Chen; Zhiyu Tang; Zhu Zeng; Weijuan Yao; Dagong Sun; Weibo Ka; Dongqi He; Zongyao Wen; Shu Chien
Journal:  Cell Motil Cytoskeleton       Date:  2006-08

3.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Authors:  N Mazurek; J C Byrd; Y Sun; M Hafley; K Ramirez; J Burks; R S Bresalier
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

4.  Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.

Authors:  Keiko Kajitani; Yuka Tanaka; Koji Arihiro; Tsuyoshi Kataoka; Hideki Ohdan
Journal:  Breast Cancer Res Treat       Date:  2012-01-20       Impact factor: 4.872

5.  Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

Authors:  Tingting Lin; Zhiying Ding; Nan Li; Jiayun Xu; Guimin Luo; Junqiu Liu; Jiacong Shen
Journal:  Eur J Cancer       Date:  2011-05-10       Impact factor: 9.162

6.  WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.

Authors:  Sireesha V Garimella; Andrea Rocca; Stanley Lipkowitz
Journal:  Mol Cancer Res       Date:  2011-11-23       Impact factor: 5.852

7.  Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles.

Authors:  Zhong-Gao Gao; Li Tian; Jun Hu; In-Suh Park; You Han Bae
Journal:  J Control Release       Date:  2011-02-02       Impact factor: 9.776

8.  Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.

Authors:  Stephanie J Ellison-Zelski; Elaine T Alarid
Journal:  Mol Cancer       Date:  2010-09-29       Impact factor: 27.401

9.  Orally active alpha-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer.

Authors:  Tobias Hahn; Karen Fried; Laurence H Hurley; Emmanuel T Akporiaye
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

10.  Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53.

Authors:  E Shankar; U Sivaprasad; A Basu
Journal:  Oncogene       Date:  2008-03-03       Impact factor: 9.867

View more
  4 in total

Review 1.  Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer.

Authors:  Lauren Bassaro; Stephen J Russell; Elzbieta Pastwa; Stella A Somiari; Richard I Somiari
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

2.  Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms.

Authors:  Guifang Yu; Xuezhu Chen; Shudi Chen; Weipeng Ye; Kailian Hou; Min Liang
Journal:  Cancer Cell Int       Date:  2015-12-12       Impact factor: 5.722

3.  Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.

Authors:  Renée T Fortner; Danja Sarink; Helena Schock; Theron Johnson; Anne Tjønneland; Anja Olsen; Kim Overvad; Aurélie Affret; Mathilde His; Marie-Christine Boutron-Ruault; Heiner Boeing; Antonia Trichopoulou; Androniki Naska; Philippos Orfanos; Domenico Palli; Sabina Sieri; Amalia Mattiello; Rosario Tumino; Fulvio Ricceri; H Bas Bueno-de-Mesquita; Petra H M Peeters; Carla H Van Gils; Elisabete Weiderpass; Eiliv Lund; J Ramón Quirós; Antonio Agudo; Maria-José Sánchez; María-Dolores Chirlaque; Eva Ardanaz; Miren Dorronsoro; Tim Key; Kay-Tee Khaw; Sabina Rinaldi; Laure Dossus; Marc Gunter; Melissa A Merritt; Elio Riboli; Rudolf Kaaks
Journal:  BMC Med       Date:  2017-02-08       Impact factor: 8.775

4.  The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction.

Authors:  Eva Koellensperger; Lilly-Claire Bonnert; Inka Zoernig; Frederik Marmé; Stefanie Sandmann; Günter Germann; Felix Gramley; Uwe Leimer
Journal:  Stem Cell Res Ther       Date:  2017-05-25       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.